Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukem...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Tam, Constantine S., Quach, Hang, Nicol, Andrew, Badoux, Xavier, Rose, Hannah, Prince, H. Miles, Leahy, Michael F., Eek, Richard, Wickham, Nicholas, Patil, Sushrut S., Huang, Jane, Prathikanti, Radha, Cohen, Aileen, Elstrom, Rebecca, Reed, William, Schneider, Jingjing, Flinn, Ian W.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2020
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556127/
https://ncbi.nlm.nih.gov/pubmed/33022066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002183
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker